BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 34147206)

  • 1. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs: past, present and future.
    Li K; Crews CM
    Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC degraders as chemical probes for studying target biology and target validation.
    Němec V; Schwalm MP; Müller S; Knapp S
    Chem Soc Rev; 2022 Sep; 51(18):7971-7993. PubMed ID: 36004812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
    Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
    Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
    Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
    Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
    He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
    Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degraders upgraded: the rise of PROTACs in hematological malignancies.
    Casan JML; Seymour JF
    Blood; 2024 Mar; 143(13):1218-1230. PubMed ID: 38170175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Validation Using PROTACs: Applying the Four Pillars Framework.
    Nowak RP; Jones LH
    SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
    Wu Y; Zhang J; Zhu X; Zhang Y
    Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.